You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your Inner Circle account to access this content. If you aren’t a member yet and would like to find out more about our Inner Circle program or sign up, click here.
The evolution of workplace health benefits is a testament to the growing awareness and sensitivity towards diverse employee needs. From mental health support to fertility and menopause benefits, employers have increasingly embraced a holistic approach to employee well-being over the past years. Now, with the recent announcement from WellTheory and Maven Clinic, there’s a compelling case that autoimmune benefits might just be…
Seattle-based biotech company, Mozart Therapeutics, has successfully raised an additional $25M in Series A financing, increasing the total funding to $80M. The company plans to channel these resources into the clinical development of their first therapeutic candidate, MTX-101, along with pipeline expansion. New investors in the round include Pfizer Ventures, AbbVie Ventures, Ono Venture Investment, and UPMC Enterprises. This additional financial commitment…
WellTheory is a virtual care platform working to reverse the autoimmune epidemic and give voice to the 50M+ Americans who struggle, often quietly, with “invisible illnesses” — conditions that are under-served and under-recognized by traditional medicine and (perhaps uncoincidentally…) disproportionately impact women and minorities. WellTheory provides this massively underserved population with personalized, evidence-based care they need to reclaim their health. Its root-cause approach…
Autoimmune disease happens when the body’s natural defense system can’t tell the difference between own cells and foreign cells, causing the body to mistakenly attack normal cells. One of the most common autoimmune diseases is multiple sclerosis (in short MS), a potentially disabling disease of the central nervous system. In MS, the immune system attacks the protective sheath that covers nerve fibers and causes…
London-based Hashimoto startup Hashiona has announced the close of a €450K pre-seed round. The company was founded in early 2020 and initially launched in January 2021. Hashiona has since acquired hundreds of beta-users, who use the app to track symptoms and connect with providers via telehealth. Draper University, KAYA, DFRI, Calm/Storm, as well as angel investors participated in the round. Hashimoto is an autoimmune disease…
